Amyotrophic Lateral Sclerosis (ALS) Clinical Trials

A listing of Amyotrophic Lateral Sclerosis (ALS) medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 37 clinical trials
Featured trial
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA)  

This is a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants,18 to 80 years of age with ALS followed by an openlabel, longterm extension period. Study ACT16970 consists …

body mass index
riluzole
edaravone
primary lateral sclerosis
  • 40 views
  • 27 Jan, 2023
  • 18 locations
  • 8 views
  • 22 Oct, 2022
  • 27 locations
Adenosine 2A Receptor Antagonism and AIH in ALS

intermittent hypoxia, or AIH), on breathing. This project will study breathing in people with amyotrophic lateral sclerosis (ALS) and unaffected, age-matched adults. Istradefylline is prescribed to increase

Accepts healthy volunteers
  • 0 views
  • 04 Oct, 2022
  • 1 location
Phase 2 Study for SAR443820 in Participants With Amyotrophic Lateral Sclerosis (ALS) (HIMALAYA)

This is a parallel treatment, Phase 2, randomized, double-blind study to assess the efficacy, safety, tolerability, PK, and PD of twice daily (BID) oral SAR443820 compared with placebo in male and female participants,18 to 80 years of age with ALS followed by an openlabel, longterm extension period. Study ACT16970 consists …

body mass index
riluzole
edaravone
primary lateral sclerosis
  • 0 views
  • 07 Oct, 2022
  • 28 locations
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

The purpose of this study is to evaluate the safety, tolerability, PK, and PD of AP-101 in participants with fALS and sALS.

assisted ventilation
edaravone
primary lateral sclerosis
riluzole
weakness
  • 0 views
  • 04 Oct, 2022
  • 9 locations
A Phase 3, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS) (COURAGE-ALS)

The purpose of this study is to assess the effect of reldesemtiv versus placebo on functional outcomes in ALS.

riluzole
edaravone
primary lateral sclerosis
weakness
  • 0 views
  • 14 Oct, 2022
  • 55 locations
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients With Amyotrophic Lateral Sclerosis (ALS) (Phoenix)

The Phoenix Trial is a randomized double blind placebo controlled Phase III trial to evaluate the safety and efficacy of AMX0035 for treatment of ALS

riluzole
edaravone
primary lateral sclerosis
treatment regimen
  • 0 views
  • 27 Oct, 2022
  • 35 locations
HEALEY ALS Platform Trial

The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.

riluzole
edaravone
treatment regimen
weakness
  • 201 views
  • 14 Oct, 2022
  • 44 locations
A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS)

The primary purpose of this study is to evaluate the clinical efficacy of ION363 on clinical function and survival in carriers of fused in sarcoma mutations with amyotrophic lateral sclerosis (FUS-ALS).

riluzole
edaravone
primary lateral sclerosis
  • 0 views
  • 23 Oct, 2022
  • 11 locations
A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the Ataxin-2 Gene (ALSpire)

Part 1: The primary objective is to evaluate the safety and tolerability of BIIB105 in participants with amyotrophic lateral sclerosis (ALS) or poly-CAG expansion (polyQ)-ALS. The secondary

edaravone
platelet count
primary lateral sclerosis
riluzole
superoxide dismutase
  • 0 views
  • 23 Oct, 2022
  • 12 locations